Tagged with BIO

China Jiangsu Hengrui Pharmaceuticals is no longer just a local biopharma heavyweight. With a record-breaking and 450x oversubscribed IPO raising USD 1.27 billion, a flurry of global licensing deals with the likes of Merck and GSK, and a bold push into competitive therapeutic areas like obesity, the company is staking its…

Switzerland Marie Leblanc brings a distinctive combination of scientific rigor and commercial acumen to her role as Executive Vice President of Life Sciences at Biosynth, drawing from an 18-year tenure at Lonza where she witnessed the evolution of the contract development and manufacturing organisation (CDMO) industry from a traditional service provider…

USA Jennifer Hawks Bland, CEO of NewYorkBIO, discusses the rapid growth and transformation of New York’s life sciences ecosystem, emphasizing the importance of policy advocacy, capital formation, and access to innovation. As New York continues to build a strong foundation for biopharma and biotech, Hawks Bland highlights how the organization is…

Global The CGT field is undergoing a critical transformation from boom to thoughtful reset. While early enthusiasm brought a rush of investment and regulatory attention, the sector is now refining its ambitions, weeding out unviable approaches, and laying the foundations for long-term impact. Companies, regulators, and healthcare systems are rethinking what…

USA Rich Bendis, CEO and founder of BioHealth Innovation, discusses how the BioHealth Capital Region has grown into a leading US life sciences hub by connecting Maryland, Washington, D.C., and Northern Virginia through a regional, collaborative approach. From supporting early-stage companies with non-dilutive funding and strategic mentoring to helping international firms…

USA John Murphy, President and CEO of the Association for Accessible Medicines (AAM), outlines a compelling vision for improving access to high-quality, affordable medicines in the US. He stresses that by directing greater focus to the generic and biosimilar market, tackling structural challenges, safeguarding supply chains, and enabling strategic domestic investment,…

Denmark Michael Kocher, Chief Executive Officer of Xellia, brings over 15 years of pharmaceutical industry experience to his leadership role at the Danish API manufacturer. Under his leadership since October 2023, the company has undertaken a comprehensive strategic realignment, divesting its US operations while refocusing on its core competencies in fermentation-based…

USA Kendalle O’Connell, President and CEO of MassBio, shares how Massachusetts has built one of the world’s most dynamic life sciences hubs through a mix of bold public investment, targeted programmes, and a “big tent” approach to collaboration. From guiding companies into the right communities with the BioReady programme to fostering…

China A roundup of some ot the biggest stories coming out of China’s biopharma industry: Chinese pharma shifts to local reagent suppliers; WuXi Biologics launches new stable cell line platform; Fosun and Expedition Therapeutics ink respiratory licensing deal, and GSK lands USD 500 million 12-drug agreement with Hengrui Pharma.   China…

Switzerland Jorge Santos da Silva is the CEO and Co-founder of MoonLake Immunotherapeutics, a Swiss biotech company known for its bold approach to drug development. With a background in neuroscience, a decade in academic research, and over 15 years at McKinsey, where he was a Senior Partner, advising pharma and biotech…

Denmark Morten Graugaard, former partner at Novo Holdings A/S, a global life science investment fund, became CEO of Orbis Medicine in February 2025. Drawing on his deep experience in life sciences and venture capital, he has led the company to raise EUR 116 million in funding, positioning Orbis as a pioneer…

China Chinese biotech is booming, led by a generation of pioneering individuals at the forefront of science and business.   A country once best known as a low-cost manufacturing destination for ‘me-too’ copycat medicines now accounts for over 28 percent of the global drug development pipeline. Western companies approaching patent cliffs…